In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Dormoi, Jérome ^a,b   Savini, Hélène ^a,b,c   Amalvict, Rémy ^a,b,d   Baret, Eric ^a,b,d   Pradines, Bruno ^a,b,d  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c LAVERAN MILITARY TEACHING HOSPITAL   (France)

^d Centre National de Reference du Paludisme   (France)

Author keywords

Anti malarial; In vitro; Malaria; Plasmodium falciparum; Resistance; statin

Indexed keywords

AMODIAQUINE; ARTEMISININ; ARTESUNATE; ATORVASTATIN; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; MEFLOQUINE; PIPERAQUINE; PYRONARIDINE; QUININE; ANTIMALARIAL AGENT; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; IC 50; IN VITRO STUDY; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; DRUG EFFECTS; DRUG SENSITIVITY; IC50;

ANTIMALARIALS; DRUG SYNERGISM; ETHANOLAMINES; FLUORENES; HEPTANOIC ACIDS; INHIBITORY CONCENTRATION 50; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PYRROLES; QUINOLINES;

EID: 84902013464     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-189     Document Type: Article

References (37)

1. Antimalarial drug resistance. Le Bras J, Musset L, Clain J, Med Mal Infect 2006 36 401 405 (Pubitemid 44425394)
2. Evidence of artemisinin-resistant malaria in western Cambodia. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, N Engl J Med 2008 359 2619 2620
3. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwrong M, Chotivanish K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467
4. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, Zhou C, Mao S, Anderson JM, Lindegardh N, Jiang H, Song J, Su XZ, White NJ, Dondorp AM, Anderson TCJ, Fay MP, Mu J, Duong S, Fairhurst RM, Lancet Infect Dis 2012 12 851 858
5. Preventing antimalarial drug resistance through combinations. White NJ, Drug Resist Updat 2001 1 3 9
6. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C, Antimicrob Agents Chemother 2007 51 2654 2655 (Pubitemid 47047361)
7. Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria. Parquet V, Briolant S, Torrentino-Madamet M, Henry M, Almeras L, Amalvict R, Baret E, Fusai T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 2248 2252
8. Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, Pradines B, J Antimicrob Chemother 2010 65 1387 1394
9. Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum. Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B, Malar J 2010 9 139
10. Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B, Antimicrob Agents Chemother 2010 54 966 967
11. Proveblue (Methylene Blue) as antimalarial agent: In vitro synergy with dihydroartemisinin and atorvastatin. Dormoi J, Pascual A, Briolant S, Amalvict R, Charras S, Baret E, Huyghues des Etages E, Feraud M, Pradines B, Antimicrob Agents Chemother 2012 56 3467 3469
12. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Borek-Dohalsky V, Huclova J, Barrett B, Nemec B, Ulc I, Jelinek I, Anal Bioanal Chem 2006 386 275 285 (Pubitemid 44327024)
13. Statins alone are ineffective in cerebral malaria but potentiate artesunate. Bienvenu AL, Picot S, Antimicrob Agents Chemother 2008 52 4203 4204
14. Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Helmers AJ, Gowda DC, Kain KC, Liles WC, Am J Trop Med Hyg 2009 81 631 637
15. Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model. Dormoi J, Briolant S, Desgrouas C, Pradines B, Malar J 2013 12 127
16. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, Pradines B, Malar J 2012 11 13
17. Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Dormoi J, Briolant S, Pascual A, Desgrouas C, Travaillé C, Pradines B, Malar J 2013 12 302
18. Synchronization of Plasmodium falciparumerythrocytic stages in culture. Lambros C, Vanderberg JP, J Parasitol 1979 65 418 420 (Pubitemid 10222999)
19. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C, Am J Trop Med Hyg 2006 74 953 959 (Pubitemid 351627399)
20. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M'Baye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonne JM, Rogier C, Fusai T, Am J Trop Med Hyg 2006 75 146 151 (Pubitemid 351627584)
21. Dihydroanthracene derivatives reverse in vitro quinoline resistance in Plasmodium falciparum malaria. Henry M, Alibert S, Baragatti M, Mosnier J, Baret E, Amalvict R, Legrand E, Fusai T, Barbe J, Rogier C, Pagès JM, Pradines B, Med Chem 2008 4 426 437
22. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G, Antimicrob Agents Chemother 2006 50 1893 1895
23. Pfmdr1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. Lim P, Akler AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongsrichanalai C, Fandeur T, Le Bras J, Ringwald P, Ariey F, Malar J 2009 8 11
24. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Price RN, Uhlemann AC, Brockman A, McReady R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, Lancet 2004 364 438 447 (Pubitemid 39036891)
25. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. Sidhu ABS, Uhlmann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA, J Infect Dis 2006 194 528 535 (Pubitemid 44162666)
26. Role of P-glycoprotein in statin drug interactions. Holtzman CW, Wiggins BS, Spinler SA, Pharmacotherapy 2006 26 1601 1607 (Pubitemid 44704473)
27. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Wang E, Casciano CN, Clement RP, Johnson WW, Pharm Res 2001 18 800 806 (Pubitemid 32783516)
28. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Wu X, Whitfield LR, Stewart BH, Pharm Res 2000 17 209 215 (Pubitemid 30158371)
29. In vitro piperaquine susceptibility is not associated with Plasmodium falciparumchloroquine resistance transporter gene. Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, Cren J, Taudon N, Rogier C, Parzy D, Pradines B, Malar J 2013 12 431
30. In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes. Hao M, Jia D, Li Q, He Y, Yuan L, Xu S, Chen K, Wu J, Shen L, Sun L, Zhao H, Yang Z, Cui L, Antimicrob Agents Chemother 2013 57 1723 1729
31. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Western, Northern, and Eastern Cambodia, 2011-2012: Association with molecular markers. Lim P, Dek D, Try V, Eastman RT, Chy S, Sreng S, Suon S, Mao S, Sopha C, Sam B, Ashley EA, Miotto O, Dondorp AM, White NJ, Su X-Z, Chuor Char M, Anderson JM, Amaratunga C, Menard D, Fairhurst RM, Antimicrob Agents Chemother 2013 57 5277 5283
32. Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses. Okombo J, Abdi AI, Kiara SM, Mwai L, Pole L, Sutherland CJ, Nzila A, Ochola-Oyier LI, Antimicrob Agents Chemother 2013 57 6196 6204
33. Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Taoufiq Z, Pino P, N'Dilimabaka N, Arrouss I, Assi S, Soubrier F, Rebollo A, Mazier D, Malar J 2011 10 52
34. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. Reis PA, Estato V, da Silva TI, d'Avila JC, Siqueira LD, Assis EF, Bozza PT, Bozza FA, Tibiriça EV, Zimmerman GA, Castro-Faria-Neto HC, PLoS Pathog 2012 8 1003099
35. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M, Lancet 2009 9 760 774
36. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S, Xenobiotica 2012 42 1088 1095
37. Profiling induction of cytochrome P450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry coktail assay in human hepatocytes. Fiedt DM, Klein K, Hofmann U, Riedmaier S, Knobeloch D, Thasler WE, Weiss TS, Schwab M, Zanger UM, Drug Metabolism Disposition 2010 38 1589 1597